{"transactions":[{"id":4637632,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-10-08T01:00:08.000Z","date":"2026-10-05","kind":"grant","planned":false,"acquired":true,"shares":64000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027."}],"balance_after":64000,"derivative":{"exercise_price":3.75,"expiration_date":"2036-10-05","underlying":"Common Stock","underlying_shares":64000},"source":{"system":"sec-edgar","filing":"0001193125-26-417234","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000119312526417234/ownership.xml","form_type":"4"}},{"id":4637631,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-08T01:00:08.000Z","date":"2026-10-05","kind":"grant","planned":false,"acquired":true,"shares":10700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027."}],"balance_after":39515,"source":{"system":"sec-edgar","filing":"0001193125-26-417234","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000119312526417234/ownership.xml","form_type":"4"}},{"id":974297,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-12-10T21:45:03.000Z","date":"2025-12-08","kind":"sale","planned":true,"acquired":false,"shares":6515,"price":14.065,"value":91633.475,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $13.75 to $14.71 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":28815,"source":{"system":"sec-edgar","filing":"0001193125-25-314735","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1250661/000119312525314735/ownership.xml","form_type":"4"}},{"id":974296,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-12-10T21:45:03.000Z","date":"2025-12-08","kind":"sale","planned":true,"acquired":false,"shares":9600,"price":13.09,"value":125664.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $12.75 to $13.69 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":35330,"source":{"system":"sec-edgar","filing":"0001193125-25-314735","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250661/000119312525314735/ownership.xml","form_type":"4"}},{"id":1067666,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2025-08-13T20:00:14.000Z","date":"2025-08-11","kind":"grant","planned":false,"acquired":true,"shares":76200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reporting person was granted this option pursuant to the 2025 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2026 annual general meeting or August 11, 2026."}],"balance_after":76200,"derivative":{"exercise_price":8.105,"expiration_date":"2030-08-11","underlying":"Ordinary Shares","underlying_shares":76200},"source":{"system":"sec-edgar","filing":"0000950170-25-108291","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1250661/000095017025108291/ownership.xml","form_type":"4"}},{"id":1067665,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-08-13T20:00:14.000Z","date":"2025-08-11","kind":"grant","planned":false,"acquired":true,"shares":12700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was granted this restricted share unit award (RSU) pursuant to the 2025 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2026 annual general meeting or August 11, 2026."}],"balance_after":44930,"source":{"system":"sec-edgar","filing":"0000950170-25-108291","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250661/000095017025108291/ownership.xml","form_type":"4"}},{"id":1433494,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2024-08-14T18:00:06.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":64460,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reporting person was granted this option pursuant to the 2024 Non-Employee Director Compensation Policy. The option vests as to 12.5% on a quarterly basis beginning August 12, 2024, through the two-year period following the grant date."}],"balance_after":64460,"derivative":{"exercise_price":5.37,"expiration_date":"2029-08-12","underlying":"Ordinary Shares","underlying_shares":64460},"source":{"system":"sec-edgar","filing":"0000950170-24-097286","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1250661/000095017024097286/ownership.xml","form_type":"4"}},{"id":1433493,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2024-08-14T18:00:06.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":32230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was granted this restricted share unit award (RSU) pursuant to the 2024 Non-Employee Director Compensation Policy. The RSU vests as to 50% on each of (i) the earlier of the Company's 2025 annual general meeting or August 12, 2025; and (ii) the earlier of the Company's 2026 annual general meeting or August 12, 2026."}],"balance_after":32230,"source":{"system":"sec-edgar","filing":"0000950170-24-097286","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250661/000095017024097286/ownership.xml","form_type":"4"}},{"id":1478861,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T21:39:43.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":13700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the options shall vest in full on the first anniversary of the grant date, subject to the reporting person's continuous service through such vesting date."}],"balance_after":13700,"derivative":{"exercise_price":0.4,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":13700},"source":{"system":"sec-edgar","filing":"0001062993-24-012664","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429560/000106299324012664/form4.xml","form_type":"4"}},{"id":1811841,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2023-08-09T20:00:21.000Z","date":"2023-08-07","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2024 annual general meeting or August 7, 2024."}],"balance_after":45000,"derivative":{"exercise_price":4.58,"expiration_date":"2028-08-07","underlying":"Ordinary Shares","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000899243-23-017913","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250661/000089924323017913/doc4.xml","form_type":"4"}},{"id":1825681,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-21T00:51:23.000Z","date":"2023-07-18","kind":"grant","planned":false,"acquired":true,"shares":34250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest and become exercisable with respect to one-tweflth (1/12) of the total number of shares subject to the options on a quarterly basis (i.e., every three months) from the Transaction Date listed above, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2023 Equity Incentive Plan, as may be amended from time to time) as of each such vesting date."}],"balance_after":34250,"derivative":{"exercise_price":0.93,"expiration_date":"2033-07-18","underlying":"Common Stock","underlying_shares":34250},"source":{"system":"sec-edgar","filing":"0001062993-23-015143","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1429560/000106299323015143/form4.xml","form_type":"4"}},{"id":2181309,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2022-08-17T20:00:42.000Z","date":"2022-08-15","kind":"grant","acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2023 annual general meeting or August 15, 2023."}],"balance_after":21000,"derivative":{"exercise_price":3.5,"expiration_date":"2027-08-15","underlying":"Ordinary Shares","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0000899243-22-029095","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250661/000089924322029095/doc4.xml","form_type":"4"}},{"id":2194353,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2022-08-04T18:19:23.000Z","date":"2022-08-02","kind":"sale","acquired":false,"shares":10297,"price":0.19,"value":1956.43,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.1900 to $0.1911, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":7203,"source":{"system":"sec-edgar","filing":"0001104659-22-086277","document":"tm2222534-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250661/000110465922086277/tm2222534-10_4seq1.xml","form_type":"4"}},{"id":2597541,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2021-08-18T18:09:43.000Z","date":"2021-08-16","kind":"grant","acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2022 annual general meeting or August 16, 2022."}],"balance_after":21000,"derivative":{"exercise_price":5.97,"expiration_date":"2026-08-16","underlying":"Ordinary Shares","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0000899243-21-033522","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250661/000089924321033522/doc4.xml","form_type":"4"}},{"id":2621105,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options","published_at":"2021-07-30T20:18:55.000Z","date":"2021-07-28","kind":"grant","acquired":false,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F2","text":"The option was granted on July 28, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One hundred percent (100%) of the option will vest on July 31, 2022, subject to the reporting person's continued service on the board of directors of Nabriva Therapeutics plc."}],"balance_after":35000,"derivative":{"exercise_price":1.08,"expiration_date":"2031-07-27","underlying":"Ordinary Shares","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001104659-21-098423","document":"tm2123737-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1250661/000110465921098423/tm2123737-3_4seq1.xml","form_type":"4"}},{"id":2621104,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-07-30T20:18:55.000Z","date":"2021-07-28","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reported transaction involved the reporting person's receipt of a grant of 17,500 restricted stock units. The total reported in Column 5 includes the 17,500 newly awarded restricted stock units."}],"balance_after":17500,"source":{"system":"sec-edgar","filing":"0001104659-21-098423","document":"tm2123737-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250661/000110465921098423/tm2123737-3_4seq1.xml","form_type":"4"}},{"id":2680701,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Options","published_at":"2021-06-04T17:50:19.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The option was granted on June 2, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest over a three-year period on a monthly pro rata basis beginning on June 2, 2021 and subject to the Reporting Person's continued service on the board of directors of the Issuer."}],"balance_after":10500,"derivative":{"exercise_price":1.39,"expiration_date":"2031-06-01","underlying":"Ordinary Shares","underlying_shares":10500},"source":{"system":"sec-edgar","filing":"0001104659-21-077205","document":"tm2118134-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250661/000110465921077205/tm2118134-5_4seq1.xml","form_type":"4"}},{"id":3050897,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2020-08-20T18:37:45.000Z","date":"2020-08-18","kind":"grant","acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2021 annual general meeting or August 18, 2021."}],"balance_after":10500,"derivative":{"exercise_price":9.13,"expiration_date":"2025-08-18","underlying":"Ordinary Shares","underlying_shares":10500},"source":{"system":"sec-edgar","filing":"0000899243-20-023093","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250661/000089924320023093/doc4.xml","form_type":"4"}},{"id":3420399,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2019-09-06T18:48:45.000Z","date":"2019-09-04","kind":"grant","acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person was granted this option pursuant to the Non-Employee Director Compensation Policy. The option vests as to 25% of the shares on September 4, 2020 and the remainder vests quarterly thereafter until September 4, 2023."}],"balance_after":21000,"derivative":{"exercise_price":21.03,"expiration_date":"2024-09-04","underlying":"Ordinary Shares","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0000899243-19-023038","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250661/000089924319023038/doc4.xml","form_type":"4"}},{"id":3450684,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2019-08-01T16:20:04.000Z","date":"2019-07-31","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is $2.38 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on July 31, 2019. One hundred percent (100%) of the option will vest on July 31, 2020, subject to the reporting person's continued service on the board of directors of Nabriva Therapeutics plc."}],"balance_after":35000,"derivative":{"expiration_date":"2029-07-31","underlying":"Ordinary Shares","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001104659-19-043346","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250661/000110465919043346/a4.xml","form_type":"4"}},{"id":3846600,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-08-13T16:30:34.000Z","date":"2018-08-09","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in twelve equal monthly installments, beginning one month after the grant date."}],"balance_after":50000,"derivative":{"exercise_price":3.33,"expiration_date":"2028-08-09","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-18-051500","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827809/000110465918051500/a4.xml","form_type":"4"}},{"id":3945404,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2018-05-04T16:03:12.000Z","date":"2018-05-02","kind":"grant","acquired":true,"shares":29000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is $4.91 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on May 2, 2018. Vesting began on May 2, 2018 and ends on May 2, 2019. One hundred percent (100%) of the option will vest on May 2, 2019."}],"balance_after":29000,"derivative":{"expiration_date":"2028-05-02","underlying":"Ordinary Shares","underlying_shares":29000},"source":{"system":"sec-edgar","filing":"0001104659-18-030626","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250661/000110465918030626/a4.xml","form_type":"4"}},{"id":4205514,"issuer":{"id":111497,"kind":"organization","name":"Nabriva Therapeutics plc","symbol":"NBRV"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2017-09-19T21:31:51.000Z","date":"2017-09-15","kind":"grant","acquired":true,"shares":10100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is $6.86 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on September 15, 2017. Vesting began on September 15, 2017 and ends on September 15, 2018. One hundred percent (100%) of the option will vest on September 15, 2018."}],"balance_after":10100,"derivative":{"expiration_date":"2027-09-15","underlying":"Ordinary Shares","underlying_shares":10100},"source":{"system":"sec-edgar","filing":"0001104659-17-057954","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250661/000110465917057954/a4.xml","form_type":"4"}},{"id":4271588,"issuer":{"id":174291,"kind":"organization","name":"Nabriva Therapeutics Legacy plc","symbol":"NBRV"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2017-06-27T21:55:21.000Z","date":"2017-06-23","kind":"other","acquired":true,"shares":10100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price is 6.634 Euro."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG.  The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2017. One hundred percent (100%) of the option will vest on August 31, 2017."}],"balance_after":10100,"derivative":{"expiration_date":"2026-08-25","underlying":"Ordinary Shares","underlying_shares":10100},"source":{"system":"sec-edgar","filing":"0001104659-17-041903","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1250661/000110465917041903/a4.xml","form_type":"4"}},{"id":4271587,"issuer":{"id":174291,"kind":"organization","name":"Nabriva Therapeutics Legacy plc","symbol":"NBRV"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2017-06-27T21:55:21.000Z","date":"2017-06-23","kind":"other","acquired":true,"shares":20200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is 6.634 Euro."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects the beneficial ownership of the reporting person following the succession pursuant to Rule 12g-3(a) of the Securities Exchange Act of 1934, as amended, of Nabriva Therapeutics plc to Nabriva Therapeutics AG.  The succession occurred following the conclusion, on June 23, 2017, of a tender offer related to the exchange of American depositary shares and common shares of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on August 26, 2016. Vesting began on August 31, 2016 and ends on August 31, 2019. This option vests on a monthly pro-rata basis at the end of each successive month following August 31, 2016."}],"balance_after":20200,"derivative":{"expiration_date":"2026-08-25","underlying":"Ordinary Shares","underlying_shares":20200},"source":{"system":"sec-edgar","filing":"0001104659-17-041903","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250661/000110465917041903/a4.xml","form_type":"4"}},{"id":4354827,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-04-11T16:02:29.000Z","date":"2017-03-30","kind":"grant","acquired":true,"shares":9600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"This Form 4/A is being filed to correct the exercise price reported in the Form 4 filed on March 31, 2017. The correct exercise price is $10.69."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The common shares underlying this stock option award will vest in equal monthly installments over 36 months, beginning one month after the grant date."}],"balance_after":9600,"derivative":{"exercise_price":10.69,"expiration_date":"2027-03-30","underlying":"Common Shares","underlying_shares":9600},"source":{"system":"sec-edgar","filing":"0001104659-17-022869","document":"a4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827809/000110465917022869/a4a.xml","form_type":"4/A","original_submission_date":"2017-03-31"}},{"id":4367501,"issuer":{"id":152369,"kind":"organization","name":"NOVELION THERAPEUTICS INC.","symbol":"NVLNF"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-03-31T16:05:16.000Z","date":"2017-03-30","kind":"grant","acquired":true,"shares":9600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The common shares underlying this stock option award will vest in equal monthly installments over 36 months, beginning one month after the grant date."}],"balance_after":9600,"derivative":{"exercise_price":10.64,"expiration_date":"2027-03-30","underlying":"Common Shares","underlying_shares":9600},"source":{"system":"sec-edgar","filing":"0001104659-17-020692","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/827809/000110465917020692/a4.xml","form_type":"4"}},{"id":4413639,"issuer":{"id":12304,"kind":"organization","name":"CoLucid Pharmaceuticals, Inc.","symbol":"CLCD"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-03-01T12:11:10.000Z","date":"2017-03-01","kind":"disposition_to_issuer","acquired":false,"shares":8897,"price":40.26,"value":358193.22,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, these options, which provided for full vesting immediately prior to the start of the Issuer's first annual meeting of stockholders following the date of grant, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest."}],"balance_after":0,"derivative":{"exercise_price":6.24,"expiration_date":"2026-05-10","underlying":"Common Stock","underlying_shares":8897},"source":{"system":"sec-edgar","filing":"0000911916-17-000066","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1250661/000091191617000066/edgar.xml","form_type":"4"}},{"id":4413638,"issuer":{"id":12304,"kind":"organization","name":"CoLucid Pharmaceuticals, Inc.","symbol":"CLCD"},"owners":[{"id":71897,"kind":"person","name":"CORRIGAN MARK","position":1,"cik":"0001250661","reported_name":"CORRIGAN MARK","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-03-01T12:11:10.000Z","date":"2017-03-01","kind":"disposition_to_issuer","acquired":false,"shares":8114,"price":42.71,"value":346548.94,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the \"Merger Agreement\"), by and among CoLucid Pharmaceuticals, Inc. (the \"Issuer\"), Eli Lilly and Company (\"Lilly\") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest."}],"balance_after":0,"derivative":{"exercise_price":3.79,"expiration_date":"2025-10-27","underlying":"Common Stock","underlying_shares":8114},"source":{"system":"sec-edgar","filing":"0000911916-17-000066","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1250661/000091191617000066/edgar.xml","form_type":"4"}}]}